Results 111 to 120 of about 1,991 (194)

Discovery of a novel cardiac-specific myosin modulator using artificial intelligence-based virtual screening [PDF]

, 2023
Attili, Seetharamaiah, Hoare, Zoe, Kampourakis, Thomas, Kenyon, Victor, Parijat, Priyanka, Shattock, Michael   +5 more
core   +3 more sources

Erratum: Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies

Frontiers in Physiology, 2022
Frontiers Production Office
doaj   +1 more source

Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography. [PDF]

JACC Case Rep
Polizzi R, Canciello G, Ordine L, Lombardi R, Esposito G, Losi MA.   +5 more
europepmc   +1 more source

Paradoxical Pulmonary Congestion After Mavacamten in Obstructive HCM: A Case Illustrating Hemodynamic Transition. [PDF]

JACC Case Rep
Tabata N, Izumiya Y, Nomura N, Kuyama N, Yamamoto E, Tsujita K.   +5 more
europepmc   +1 more source

Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors. [PDF]

ESC Heart Fail
Erzeel J, Dhont S, van Es M, Ulgar D, Bertrand P, Mullens W, Martens P.   +6 more
europepmc   +1 more source

Still at sea: a patient's ongoing journey with non-obstructive hypertrophic cardiomyopathy. [PDF]

Eur Heart J Case Rep
Goldie FC, Myles RC, Coats CJ.
europepmc   +1 more source

One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling. [PDF]

Eur Heart J Case Rep
Seuthe K, Pfister R, Schönherr CH, Kaya K, Pennig L.   +4 more
europepmc   +1 more source

Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure-strain analysis. [PDF]

Clin Res Cardiol
Scholtz S, Coppée C, Mohemed K, Potratz M, Langkamp F, Rudolph V, Maack C, Scholtz W, Sequeira V, Reil JC.   +9 more
europepmc   +1 more source

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy. [PDF]

Eur J Clin Pharmacol
Kasolo Y, Burford E, Obeidat M, Beaman GM, Monk T, Bastiaenen R, Newman WG, Cooper RM.   +7 more
europepmc   +1 more source

Medicina traslacional en el tratamiento de la miocardiopatía hipertrófica: Mavacantem "La nueva promesa" [PDF]

Diaz- Beltrán, Juan Camilo, Madroñero - Lenis, Junior Rene, Serna Trejos, Juan Santiago   +2 more
core   +1 more source